Combination treatment strategies with a focus on rosiglitazone and adriamycin for insulin resistant liver cancer

References

• Dirk JS, Frank AJLS, Patrick S, et al. Circadian clocks and insulin resistance. Nat Rev Endocrinol. 2018;15:75–89.
   Web of Science ®Google Scholar
• Altaf QA, Barnett AH, Tahrani AA. Novel therapeutics for type 2 diabetes: insulin resistance. Diabetes Obes Metab. 2015;17(4):319–334.
   PubMed Web of Science ®Google Scholar
• Vivacqua A, De MP, Belfiore A, et al. Recent advances on the role of microRNAs in both insulin resistance and cancer. Curr Pharm Des. 2017;23(25):3658–3666.
   PubMed Web of Science ®Google Scholar
• Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174.
   PubMed Web of Science ®Google Scholar
• Farrell G. Insulin resistance, obesity, and liver cancer. Clin Gastroenterol Hepatol. 2014;12(1):117–119.
   PubMed Web of Science ®Google Scholar
• Bo QF, Sun X, Liu J, et al. Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma. Oncol Lett. 2015;10(4):1979–1984.
   PubMed Web of Science ®Google Scholar
• Zanardelli M, Micheli L, Cinci L, et al. Oxaliplatin neurotoxicity involves peroxisome alterations. pparγ agonism as preventive pharmacological approach. PLoS One. 2014;9(7):e102758.
   PubMed Web of Science ®Google Scholar
• Jiang M, Huang O, Xie ZQ, et al. A novel long non-coding rna-ara: adriamycin resistance-associated. Biochem Pharmacol. 2014;87(2):254–283.
   PubMed Web of Science ®Google Scholar
• Huang YX, Cai YJ, Huang RG, et al. Rosmarinic acid combined with adriamycin induces apoptosis by triggering mitochondria mediated signaling pathway in HepG2 and Bel- 7402 cells. Med Sci Monit. 2018;24:7898–7908.
   PubMed Web of Science ®Google Scholar
• Liu XY, Li LJ, Li J, et al. Insulin resistance contributes to multidrug resistance in HepG2 cells via activation of the PERK signaling pathway and upregulation of Bcl-2 and P-gp. Oncol Rep. 2016;35(5):3018–3024.
   PubMed Web of Science ®Google Scholar
• Wang GH, Jin J, Sun LZ. Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats. Endocr J. 2018;65(9):903–913.
   PubMed Web of Science ®Google Scholar
• Chen KL, Chang WSW, Cheung CHA, et al. Targeting cathepsin S induces tumor cell autophagy via the EGFR–ERK signaling pathway. Cancer Lett. 2012;317(1):89–98.
   PubMed Web of Science ®Google Scholar
• Zhou XS, Zhou R, Li QW, et al. Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K/Akt/mTOR pathway. Anticancer Drugs. 2019;30(3):241–250.
   PubMed Web of Science ®Google Scholar
• Su Q, Sun F, Li J, et al. The correlation analysis of primary liver cancer with type 2 diabetes. Indian J Cancer. 2015;52(7):148.
   Web of Science ®Google Scholar
• Pu XJ, Li J, Zhou QL, et al. Rosiglitazone inhibits PM2.5-induced cytotoxicity in human lung epithelial A549 cells. Ann Transl Med. 2018;6(8):152–152.
   PubMed Web of Science ®Google Scholar
• Lau MF, Vellasamy S, Chua KH, et al. Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells. Excli J. 2018;17:186–199.
   PubMed Web of Science ®Google Scholar
• Nakamaru K, Matsumoto K, Taguchi T, et al. AICAR, an activator of AMP-activated protein kinase, down-regulates the insulin receptor expression in HepG2 cells. Biochem Biophys Res Commun. 2005;328(2):449–454.
   PubMed Web of Science ®Google Scholar
• Yoshizato K, Shirotani T, Furukawa N, et al. Identification of a cis-acting element and a novel trans-acting factor of the human insulin receptor gene in HepG2 and rat liver cells. Biochem Biophys Res Commun. 2001;280(2):428–434.
   PubMed Web of Science ®Google Scholar
• Fan XM, Tao JY, Zhou YL, et al. Investigations on the effects of ginsenoside-Rg1 on glucose uptake and metabolism in insulin resistant HepG2 cells. Eur J Pharmacol. 2019;843:277–284.
   PubMed Web of Science ®Google Scholar
• Chen MJ, Wu LM, Tu JF, et al. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression. EBioMedicine. 2018;35:142–154.
   PubMed Web of Science ®Google Scholar
• Alfarouk KO, Stock CM, Taylor S, et al. Resistance to cancer chemotherapy: failure in drug response from adme to p-gp. Cancer Cell Int. 2015;15(1):71.
   PubMed Web of Science ®Google Scholar
• Joshi P, Vishwakarma RA, Bharate SB. Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer. Eur J Med Chem. 2017;138:273–292.
   PubMed Web of Science ®Google Scholar
• Di Fazio P, Matrood S. Targeting autophagy in liver cancer. Transl Gastroenterol Hepatol. 2018;3:39–39.
   PubMed Web of Science ®Google Scholar
• Lu HP, Han M, Yuan XX, et al. Role of IL-6-mediated expression of NS5ATP9 in autophagy of liver cancer cells: IL-6 induces autophagy depends on NS5ATP9. J Cell Physiol. 2018;233(12):9312–9319.
   PubMed Web of Science ®Google Scholar
• Zhang N, Cao MM, Liu H, et al. Autophagy regulates insulin resistance following endoplasmic reticulum stress in diabetes. J Physiol Biochem. 2015;71(2):319–327.
   PubMed Web of Science ®Google Scholar
• Shi Y, Han JJ, Tennakoon JB, et al. Androgens promote prostate cancer cell growth through induction of autophagy. Mol Endocrinol. 2013;27(2):280–295.
   PubMedGoogle Scholar
• Wang FF, Chen J, Zhang ZW, et al. Differences of basic and induced autophagic activity between K562 and K562/ADM cells. Intractable Rare Dis Res. 2017;6(4):281–290.
   PubMed Web of Science ®Google Scholar
• Wang GY, Huo XK, Wang LJ, et al. Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: more than just down-regulation of MDR1. Sci Rep. 2016;6:28403.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei Y, Li X, et al. microRNA-874 suppresses tumor proliferation and metastasis in hepatocellular carcinoma by targeting the DOR/EGFR/ERK pathway. Cell Death Dis. 2018;9(2):130.
   PubMedGoogle Scholar
• Li ZD, Rong L, Lian HF, et al. Knockdown MTMR14 promotes cell apoptosis and inhibits migration in liver cancer cells. Gene. 2019;691:106–113.
   PubMed Web of Science ®Google Scholar
• Keku TO, Lund PK, Galanko J, et al. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2076–2081.
   PubMed Web of Science ®Google Scholar
• Fabregat I, Roncero C, Fernández M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 2007;27(2):155–162.
   PubMed Web of Science ®Google Scholar
• Lopiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the pi3k/akt/mtor pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008;11(1–2):32–50.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yan L, Zhu W, et al. MMP2/3 promote the growth and migration of laryngeal squamous cell carcinoma via PI3K/Akt-NF-κB-mediated epithelial-mesenchymal transformation. J Cell Physiol. 2019;234(9):11391–15847.
   PubMed Web of Science ®Google Scholar
• Chen T, Wang Q, Li Y, et al. Chinese herbal formula qhf inhibits liver cancer cell invasion and migration. Exp Ther Med. 2016;11(6):2413–2419.
   PubMed Web of Science ®Google Scholar